Regeneron requests emergency approval for antibody treatment taken by Trump; stock rises 4% in pre-market – CNBC

Regeneron’s stock price rose over 4% in pre-market trade Thursday, as it submitted an “emergency use authorization” (EUA) request to the U.S. Food and Drug Administration for its Covid-19 antibody tr… [read more]

Leave a Reply

Your email address will not be published. Required fields are marked *